Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Cardiac macrophages regulate isoproterenol-induced Takotsubo-like cardiomyopathy
Xudong Liao, Eugene Chang, Xinmiao Tang, Ippei Watanabe, Rongli Zhang, Hyun-Woo Jeong, Ralf H. Adams, Mukesh K. Jain
Xudong Liao, Eugene Chang, Xinmiao Tang, Ippei Watanabe, Rongli Zhang, Hyun-Woo Jeong, Ralf H. Adams, Mukesh K. Jain
View: Text | PDF
Research Article Cardiology

Cardiac macrophages regulate isoproterenol-induced Takotsubo-like cardiomyopathy

  • Text
  • PDF
Abstract

Takotsubo syndrome (TTS) is an acute, stress-induced cardiomyopathy that occurs predominantly in women after extreme physical and/or emotional stress. To date, our understanding of the molecular basis for TTS remains unknown and, consequently, specific therapies are lacking. Myocardial infiltration of monocytes and macrophages in TTS has been documented in clinical studies. However, the functional importance of these findings remains poorly understood. Here, we show that a single high dose of isoproterenol (ISO) in mice induced a TTS-like cardiomyopathy phenotype characterized by female predominance, severe cardiac dysfunction, and robust myocardial infiltration of macrophages. Single-cell RNA-Seq studies of myocardial immune cells revealed that TTS-like cardiomyopathy is associated with complex activation of innate and adaptive immune cells in the heart, and macrophages were identified as the dominant immune cells. Global macrophage depletion (via clodronate liposome administration) or blockade of macrophage infiltration (via a CCR2 antagonist or in CCR2-KO mice) resulted in recovery of cardiac dysfunction in ISO-challenged mice. In addition, damping myeloid cell activation by HIF1α deficiency or exposure to the immunomodulatory agent bortezomib ameliorated ISO-induced cardiac dysfunction. Collectively, our findings identify macrophages as a critical regulator of TTS pathogenesis that can be targeted for therapeutic gain.

Authors

Xudong Liao, Eugene Chang, Xinmiao Tang, Ippei Watanabe, Rongli Zhang, Hyun-Woo Jeong, Ralf H. Adams, Mukesh K. Jain

×

Figure 7

Pharmacological inhibition of myeloid activation ameliorates ISO-induced TTS-like cardiomyopathy.

Options: View larger image (or click on image) Download as PowerPoint
Pharmacological inhibition of myeloid activation ameliorates ISO-induced...
(A) Representative FACS plots of myocardial cells. P1, macrophages; P2, neutrophils. (B and C) Changes in cardiac macrophages (B) and neutrophils (C). n = 4–7. (D) Cardiac function in ISO-treated mice with or without BZ therapy. n = 8–14. (E) Cell death in the myocardium detected by TUNEL staining. (F) Myocardial fibrosis detected by picrosirius red staining. Boxed areas shown in high magnification on the right. Representative images are from 5 to 10 mice in each group. Scale bar: 50 μm. (G and H) Effects of BZ on cardiomyocytes (G) and macrophages (H) in vitro. n = 6 in each group. BZ dose, 5 μM, added 6 hours before phenylephrine (PE; 50 μM, treated for 24 hours) or LPS (50 ng/mL; treated for 24 hours). (A–D) One day after ISO administration. (E and F) Seven days after ISO administration. BZ treatment started 3 days before ISO administration (0.3 mg/kg i.p. every either day). (D) P values were from 2-tailed unpaired Student t test. (B and C) P values were from a 1-way ANOVA post hoc test with Tukey correction. (G and H) P values were from a 2-way ANOVA post hoc test with Tukey correction.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts